Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
Main Authors: | Liping Ye, Chuyong Lin, Xi Wang, Qiji Li, Yue Li, Meng Wang, Zekun Zhao, Xianqiu Wu, Dongni Shi, Yunyun Xiao, Liangliang Ren, Yunting Jian, Meisongzhu Yang, Ruizhang Ou, Guangzheng Deng, Ying Ouyang, Xiangfu Chen, Jun Li, Libing Song |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer Nature
2022-03-01
|
Series: | EMBO Molecular Medicine |
Online Access: | https://doi.org/10.15252/emmm.202115618 |
Similar Items
-
Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
by: Liping Ye, et al.
Published: (2019-12-01) -
SALL4 Oncogenic Function in Cancers: Mechanisms and Therapeutic Relevance
by: Boshu Sun, et al.
Published: (2022-02-01) -
A Wnt-induced lncRNA-DGCR5 splicing switch drives tumor-promoting inflammation in esophageal squamous cell carcinoma
by: Yue Li, et al.
Published: (2023-06-01) -
Durable CRISPR-Based Epigenetic Silencing
by: Muneaki Nakamura, et al.
Published: (2021-01-01) -
Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer
by: Muwen Yang, et al.
Published: (2023-07-01)